Icon (ICLR) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Icon (NASDAQ:ICLR) announced its quarterly earnings results on Thursday. The medical research company reported $1.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.41 by $0.02, Morningstar.com reports. The company had revenue of $455.10 million during the quarter, compared to analyst estimates of $455.66 million. Icon had a return on equity of 28.42% and a net margin of 16.37%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $1.33 earnings per share. Icon updated its FY18 guidance to $5.89-6.09 EPS.

Icon (NASDAQ ICLR) opened at $110.19 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a 1-year low of $76.46 and a 1-year high of $124.48. The company has a market capitalization of $5,922.06, a P/E ratio of 21.35, a price-to-earnings-growth ratio of 1.54 and a beta of 0.48.

A number of large investors have recently added to or reduced their stakes in the business. Clark Capital Management Group Inc. lifted its holdings in Icon by 12.6% during the 4th quarter. Clark Capital Management Group Inc. now owns 124,535 shares of the medical research company’s stock worth $13,967,000 after buying an additional 13,889 shares during the last quarter. Raymond James & Associates lifted its holdings in Icon by 7.1% during the 4th quarter. Raymond James & Associates now owns 87,959 shares of the medical research company’s stock worth $9,865,000 after buying an additional 5,833 shares during the last quarter. HBK Investments L P bought a new position in Icon during the 4th quarter worth approximately $886,000. Two Sigma Investments LP lifted its holdings in Icon by 34.3% during the 4th quarter. Two Sigma Investments LP now owns 62,985 shares of the medical research company’s stock worth $7,064,000 after buying an additional 16,080 shares during the last quarter. Finally, Deutsche Bank AG lifted its holdings in Icon by 20.9% during the 4th quarter. Deutsche Bank AG now owns 255,932 shares of the medical research company’s stock worth $28,701,000 after buying an additional 44,287 shares during the last quarter. 89.66% of the stock is currently owned by institutional investors.

ICLR has been the subject of several analyst reports. Barclays upped their target price on Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Friday, October 27th. SunTrust Banks reissued a “buy” rating and issued a $138.00 price target on shares of Icon in a report on Sunday, October 29th. Zacks Investment Research downgraded Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. KeyCorp reissued an “overweight” rating and issued a $125.00 price target (up previously from $115.00) on shares of Icon in a report on Monday, November 13th. They noted that the move was a valuation call. Finally, ValuEngine raised Icon from a “hold” rating to a “buy” rating in a report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $124.55.

TRADEMARK VIOLATION WARNING: “Icon (ICLR) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/15/icon-iclr-issues-quarterly-earnings-results-beats-estimates-by-0-02-eps.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply